Cover
Cover - shares | 3 Months Ended | |
Mar. 31, 2021 | May 03, 2021 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2021 | |
Document Transition Report | false | |
Entity File Number | 001-36296 | |
Entity Registrant Name | Sesen Bio, Inc. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 26-2025616 | |
Entity Address, Address Line One | 245 First Street | |
Entity Address, Address Line Two | Suite 1800 | |
Entity Address, City or Town | Cambridge | |
Entity Address, State or Province | MA | |
Entity Address, Postal Zip Code | 02142 | |
City Area Code | 617 | |
Local Phone Number | 444-8550 | |
Title of 12(b) Security | Common Stock, $0.001 par value | |
Trading Symbol | SESN | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Small Business | true | |
Entity Filer Category | Non-accelerated Filer | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 173,287,287 | |
Entity Central Index Key | 0001485003 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash and cash equivalents | $ 109,965 | $ 52,389 |
Accounts receivables | 2,886 | 0 |
Prepaid expenses and other current assets | 13,728 | 7,478 |
Restricted cash | 0 | 3,000 |
Total current assets | 126,579 | 62,867 |
Restricted cash | 20 | 20 |
Property and equipment, net of accumulated depreciation of $911 and $882, respectively | 93 | 123 |
Intangible assets | 46,400 | 46,400 |
Goodwill | 13,064 | 13,064 |
Other assets | 258 | 349 |
Total Assets | 186,414 | 122,823 |
Current liabilities: | ||
Accounts payable | 2,004 | 3,102 |
Accrued expenses | 3,538 | 3,973 |
Deferred revenue | 1,500 | 1,500 |
Other current liabilities | 490 | 489 |
Total current liabilities | 17,367 | 18,049 |
Deferred revenue, net of current portion | 0 | 1,500 |
Deferred tax liability | 12,528 | 12,528 |
Other liabilities | 84 | 118 |
Total Liabilities | 177,144 | 132,050 |
Stockholders’ Equity ( Deficit): | ||
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at March 31, 2021 and December 31, 2020; no shares issued and outstanding at March 31, 2021 and December 31, 2020 | 0 | 0 |
Common stock, $0.001 par value per share; 200,000,000 shares authorized at March 31, 2021 and December 31, 2020; 171,978,799 and 140,449,647 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively | 172 | 140 |
Additional paid-in capital | 380,531 | 306,554 |
Accumulated deficit | (371,433) | (315,921) |
Total Stockholders’ Equity (Deficit) | 9,270 | (9,227) |
Total Liabilities and Stockholders’ Equity (Deficit) | $ 186,414 | $ 122,823 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Statement of Financial Position [Abstract] | ||
Property and equipment, accumulated depreciation | $ 911 | $ 882 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 200,000,000 | 200,000,000 |
Common stock, shares issued (in shares) | 171,978,799 | 140,449,647 |
Common stock, shares outstanding (in shares) | 171,978,799 | 140,449,647 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Income Statement [Abstract] | ||
License revenue | $ 4,310 | $ 0 |
Operating expenses: | ||
Research and development | 6,078 | 8,867 |
General and administrative | 5,293 | 3,448 |
Change in fair value of contingent consideration | 48,160 | (53,700) |
Total operating expenses | 59,531 | (41,385) |
(Loss) Income from operations | (55,221) | 41,385 |
Other (expense) income, net: | ||
Other (expense) income, net | (3) | 179 |
Net (Loss) Income and Comprehensive (Loss) Income Before Taxes | (55,224) | 41,564 |
Provision for income taxes | (288) | 0 |
Net (Loss) Income and Comprehensive (Loss) Income After Taxes | (55,512) | 41,564 |
Net (loss) income attributable to common stockholders - basic | (55,512) | 34,407 |
Net (loss) income attributable to common stockholders - diluted | $ (55,512) | $ 34,408 |
Earnings Per Share [Abstract] | ||
Net (loss) per common share - basic (in dollars per share) | $ (0.35) | $ 0.31 |
Weighted-average common shares outstanding - basic (in shares) | 157,033 | 109,808 |
Net income (loss) per share applicable to common stockholders - diluted (in dollars per share) | $ (0.35) | $ 0.31 |
Weighted-average common shares outstanding for diluted (in shares) | 157,033 | 109,823 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-in Capital | Accumulated Deficit |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Beginning balance (in shares) | 106,801,409 | |||
Beginning balance (in shares) | 109,991,553 | |||
Beginning balance at Dec. 31, 2019 | $ (26,700) | $ 107 | $ 266,717 | $ (293,524) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Net loss | 41,564 | 41,564 | ||
Share-based compensation | 407 | 407 | ||
Sale of common stock under 2014 ESPP (in shares) | 2,785 | |||
Sales of common stock under 2014 ESPP | 1 | 1 | ||
Issuance of common stock under ATM offering, net of issuance costs (in shares) | 3,187,359 | |||
Issuance of common stock under ATM offering, net of issuance costs | 3,179 | $ 3 | 3,176 | |
Ending balance (in shares) at Mar. 31, 2020 | 109,991,553 | |||
Ending balance at Mar. 31, 2020 | 18,451 | $ 110 | 270,301 | (251,960) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Beginning balance (in shares) | 109,991,553 | |||
Beginning balance (in shares) | 140,449,647 | |||
Beginning balance (in shares) | 171,978,799 | |||
Beginning balance at Dec. 31, 2020 | (9,227) | $ 140 | 306,554 | (315,921) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Net loss | (55,512) | (55,512) | ||
Share-based compensation | $ 958 | 958 | ||
Exercise of stock options (in shares) | 31,000 | 30,610 | ||
Exercises of stock options | $ 39 | 39 | ||
Exercise of common stock warrants (in shares) | 853,000 | 852,840 | ||
Exercises of common stock warrants | $ 469 | $ 1 | 468 | |
Issuance of common stock under ATM offering, net of issuance costs (in shares) | 30,645,702 | |||
Issuance of common stock under ATM offering, net of issuance costs | 72,543 | $ 31 | 72,512 | |
Ending balance (in shares) at Mar. 31, 2021 | 171,978,799 | |||
Ending balance at Mar. 31, 2021 | $ 9,270 | $ 172 | $ 380,531 | $ (371,433) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||
Beginning balance (in shares) | 171,978,799 |
CONDENSED CONSOLIDATED STATEM_3
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) - USD ($) $ in Millions | 3 Months Ended | ||
Mar. 31, 2021 | Sep. 30, 2020 | Mar. 31, 2020 | |
Statement of Stockholders' Equity [Abstract] | |||
Issuance of common stock, issuance costs | $ 2.2 | $ 0.1 | $ 0.1 |
CONDENSED CONSOLIDATED STATEM_4
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | |
Cash Flows from Operating Activities: | |||
Net (loss) income | $ (55,512) | $ 41,564 | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Depreciation | 30 | 31 | |
Share-based compensation | 958 | 407 | |
Change in fair value of contingent consideration | 48,160 | (53,700) | |
Changes in operating assets and liabilities: | |||
Accounts receivable (net) | (2,886) | 0 | |
Prepaid expenses and other assets | (6,159) | 4,011 | |
Accounts payable | (1,098) | 166 | |
Accrued expenses and other liabilities | (468) | (1,317) | |
Deferred revenue (ST and LT) | (1,500) | 0 | |
Net Cash Used in Operating Activities | (18,475) | (8,838) | $ (30,800) |
Cash Flows from Investing Activities: | |||
Net Cash Used in Investing Activities | 0 | 0 | |
Cash Flows from Financing Activities: | |||
Proceeds from issuance of common stock under ATM Offering, net of issuance costs | 72,543 | 3,179 | |
Proceeds from sales of common stock under 2014 ESPP | 0 | 1 | |
Proceeds from exercises of stock options | 39 | 0 | |
Proceeds from the exercise of common stock warrants | 469 | 0 | |
Net Cash Provided by Financing Activities | 73,051 | 3,180 | |
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash | 54,576 | (5,658) | |
Cash, Cash Equivalents and Restricted Cash - Beginning of Period | 55,409 | 48,141 | 48,141 |
Cash, Cash Equivalents and Restricted Cash - End of Period | 109,985 | 42,483 | $ 55,409 |
Supplemental disclosure of non-cash activities | |||
Cash paid for amounts included in the measurement of lease liabilities | $ 43 | $ 38 |
DESCRIPTION OF BUSINESS
DESCRIPTION OF BUSINESS | 3 Months Ended |
Mar. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Description of Business | DESCRIPTION OF BUSINESS Sesen Bio, Inc. ("Sesen" or the “Company”), a Delaware corporation formed in February 2008, is a late-stage clinical company advancing targeted fusion protein therapeutics ("TFPTs") for the treatment of patients with cancer. The Company’s most advanced product candidate, Vicineum TM , also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus Calmette-Guerin ("BCG")-unresponsive non-muscle invasive bladder cancer ("NMIBC"). The Company has an ongoing single-arm, multi-center, open-label Phase 3 clinical trial of Vicineum as a monotherapy in patients with BCG-unresponsive NMIBC (the "VISTA Trial"). The VISTA Trial completed enrollment in April 2018 with a total of 133 patients. On December 18, 2020, the Company submitted its completed Biologics License Application (the "BLA") for Vicineum for the treatment of BCG-unresponsive NMIBC to the United States Food and Drug Administration ("FDA"). On February 12, 2021, the FDA notified the Company that it has accepted for filing the BLA. The FDA also granted Priority Review for the BLA and the anticipated target PDUFA date for a decision on the BLA is August 18, 2021. In addition to the file acceptance and granting of Priority Review, the FDA also indicated that it is not currently planning to hold an advisory committee meeting to discuss the BLA for Vicineum. The Company operates in one segment under the direction of its Chief Executive Officer (chief operating decision maker). The Company was formerly known as Eleven Biotherapeutics, Inc. until its name changed in May 2018. Viventia Acquisition In September 2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada ("Viventia"), the shareholders of Viventia named therein (the “Selling Shareholders”) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (“Clairmark”) (the “Share Purchase Agreement”), pursuant to which the Company agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the “Viventia Acquisition”). In connection with the closing of the Viventia Acquisition, the Company issued 4.0 million shares of its common stock to the Selling Shareholders, which at that time represented approximately 19.9% of the voting power of the Company as of immediately prior to the issuance of such shares. Clairmark is an affiliate of Leslie L. Dan, who served as a director of the Company until his retirement in July 2019. In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i) a one-time milestone payment of $12.5 million payable upon the first sale of Vicineum (the “Purchased Product”) in the United States; (ii) a one-time milestone payment of $7 million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $3 million payable upon the first sale of the Purchased Product in Japan; and (iv) quarterly earn-out payments equal to 2% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033 and (ii) fifteen years after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country (collectively, the "Contingent Consideration"). Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts for the first seven years following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that became employees or members of the Company's board of directors, however as of March 31, 2021, none of these individuals are active employees or members of the Company's board of directors. Liquidity and Going Concern As of March 31, 2021, the Company had cash and cash equivalents of $110 million, net working capital of $109.2 million and an accumulated deficit of $371.4 million. The Company incurred negative cash flows from operating activities of $30.8 million for the year ended December 31, 2020 and $18.5 million for the three months ended March 31, 2021. Since its inception, the Company has received no revenue from sales of its products, and management anticipates that operating losses will continue as the Company continues into the follow-up stage of its ongoing Phase 3 VISTA Trial for Vicineum for the treatment of BCG-unresponsive NMIBC and seeks marketing approval from the FDA and the European Medicines Agency, and if approved, commercializes Vicineum. The Company has financed its operations to date primarily through private placements of its common stock, preferred stock, common stock warrants and convertible bridge notes, venture debt borrowings, its initial public offering ("IPO"), follow-on public offerings, sales effected in "at-the-market" ("ATM") offerings, out-licensing agreements and OUS business development partnership agreements, and, to a lesser extent, from a collaboration. See “Note 9. Stockholders’ Equity (Deficit)” below for information regarding the Company’s recently completed equity financings. Under Accounting Standards Codification ("ASC") Topic 205-40, Presentation of Financial Statements - Going Concern , management is required at each reporting period to evaluate whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management's plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered probable of being effectively implemented, the plans must have been approved by the Company's board of directors before the date that the financial statements are issued. The Company's future success is dependent on its ability to develop and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC, and ultimately upon its ability to attain profitable operations. In order to commercialize its product candidates, including Vicineum for the treatment of BCG-unresponsive NMIBC, the Company needs to complete clinical development and comply with comprehensive regulatory requirements. The Company is subject to a number of risks similar to other late-stage clinical companies, including, but not limited to, successful discovery and development of its product candidates, raising additional capital, development and commercialization by its competitors of new technological innovations, protection of proprietary technology, market acceptance of its products and dependence on third parties for the development and commercialization of Vicineum in certain markets. The successful discovery and development of product candidates, including Vicineum for the treatment of BCG-unresponsive NMIBC, requires substantial working capital, and management expects to seek additional funds through equity or debt financings or through additional business development partnerships, collaborations or licensing transactions or other sources. The Company may be unable to obtain equity or debt financings or enter into additional business development partnerships, collaborations or licensing transactions on favorable terms, or at all. To the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interests of existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financing, if available, may involve agreements that include liens or other restrictive covenants limiting the Company's ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Company raises additional funds through government or other third-party funding, strategic collaborations, business development agreements, partnerships, alliances or licensing arrangements, it may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable. If the Company is unable to raise additional funds when needed, it may be required to implement cost reduction strategies and delay, limit, reduce or terminate its product development, regulatory approval or future commercialization efforts or grant rights to develop and market products or product candidates that management would otherwise prefer to develop and market. The Company's management does not believe that its cash and cash equivalents of $110 million as of March 31, 2021 are sufficient to fund the Company's current operating plan for at least twelve months after the issuance of these condensed consolidated financial statements. Given the history of significant losses, negative cash flows from operations, limited cash resources currently on hand, the impact of the ongoing COVID-19 pandemic on the capital markets, and dependence by the Company on its ability - about which there can be no certainty - to obtain additional financing to fund its operations after the current cash resources are exhausted, substantial doubt exists about the Company's ability to continue as a going concern. These condensed consolidated financial statements were prepared under the assumption that the Company will continue as a going concern and do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. |
BASIS OF PRESENTATION
BASIS OF PRESENTATION | 3 Months Ended |
Mar. 31, 2021 | |
Accounting Policies [Abstract] | |
BASIS OF PRESENTATION | BASIS OF PRESENTATION The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and Accounting Standards Updates (“ASUs”), promulgated by the Financial Accounting Standards Board (“FASB”). Interim Financial Statements The accompanying unaudited interim condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United States Securities and Exchange Commission (“SEC”), which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the accompanying condensed consolidated balance sheets and statements of operations and comprehensive (loss) income, stockholders’ equity (deficit) and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. These unaudited interim results of operations and cash flows for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the full year. These unaudited interim condensed consolidated financial statements and footnotes should be read in conjunction with the Company’s audited annual consolidated financial statements and footnotes included in its Annual Report on Form 10-K, as filed with the SEC on March 15, 2021, wherein a more complete discussion of significant accounting policies and certain other information can be found. Use of Estimates The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company’s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets, goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); research and development expenses; revenue recognition and going concern considerations. Principles of Consolidation The Company’s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation. Foreign Currency Translation The functional currency of the Company and each of its subsidiaries is the U.S. dollar. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 3 Months Ended |
Mar. 31, 2021 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESThe Company's complete summary of significant accounting policies can be found in "Item 15. Exhibits and Financial Statement Schedules - Note 3. Summary of Significant Accounting Policies" in the audited annual consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2020. |
RECENT ACCOUNTING PRONOUNCEMENT
RECENT ACCOUNTING PRONOUNCEMENTS | 3 Months Ended |
Mar. 31, 2021 | |
Accounting Standards Update and Change in Accounting Principle [Abstract] | |
RECENT ACCOUNTING PRONOUNCEMENTS | RECENT ACCOUNTING PRONOUNCEMENTS Adopted in 2021 In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments in ASU 2019-12 also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. The method with which the amendments in this ASU are to be applied varies depending on the nature of the tax item impacted by amendment. The Company adopted this guidance effective January 1, 2021, and it did not have a material impact on its financial position, results of operations or cash flows. |
FAIR VALUE MEASUREMENT AND FINA
FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS | 3 Months Ended |
Mar. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS | FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company’s condensed consolidated balance sheets approximated their fair values as of March 31, 2021 and December 31, 2020 due to their short-term nature. Certain of the Company’s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: Level 1 : Inputs are quoted prices for identical instruments in active markets. Level 2 : Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. Level 3 : Inputs are unobservable and reflect the Company’s own assumptions, based on the best information available, including the Company’s own data. The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in thousands): March 31, 2021 Fair Value Measurement Based on Carrying Amount Fair Value Quoted Prices in Active Significant Other Observable Significant Unobservable Assets: Money market funds $ 16,377 $ 16,377 $ 16,377 $ — $ — Liabilities: Contingent consideration - short term $ 9,835 $ 9,835 $ — $ — $ 9,835 Contingent consideration - long term 147,165 147,165 — — 147,165 December 31, 2020 Fair Value Measurement Based on Carrying Amount Fair Value Quoted Prices in Active Significant Other Observable Significant Unobservable Assets: Money market funds $ 16,374 $ 16,374 $ 16,374 $ — $ — Liabilities: Contingent consideration - short term $ 8,985 $ 8,985 $ — $ — $ 8,985 Contingent consideration - long term 99,855 $ 99,855 — — 99,855 The Company evaluates transfers between fair value levels at the end of each reporting period. There were no transfers of assets or liabilities between fair value levels during the three months ended March 31, 2021. Contingent Consideration On September 20, 2016, the Company acquired Viventia through the issuance of shares of common stock plus contingent consideration, pursuant to the terms of a Share Purchase Agreement. The Company recorded the acquired assets and liabilities based on their estimated fair values as of the acquisition date and finalized its purchase accounting for the Viventia Acquisition during the third quarter of 2017. The contingent consideration relates to amounts potentially payable to the former shareholders of Viventia under the Share Purchase Agreement. Contingent consideration is measured at its estimated fair value at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant inputs, including internally developed financial forecasts, probabilities of success, and the timing of certain milestone events and achievements, which are not observable in the market, representing a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. The estimated fair value of the Company’s contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved ranging from 2021 to 2033, the level of commercial sales of Vicineum forecasted for the United States, Europe, Japan, China and other potential markets and discount rates ranging from 7.4% to 7.8% as of March 31, 2021 and 8.4% to 8.8% as of December 31, 2020. There have been no changes to the valuation methods utilized during the three months ended March 31, 2021. The following table sets forth a summary of the change in the fair value of the Company's total contingent consideration liability, measured on a recurring basis at each reporting period, for the three months ended March 31, 2021 (in thousands): Balance at December 31, 2020 $108,840 Change in fair value of contingent consideration - short term 850 Change in fair value of contingent consideration - long term 47,310 Balance at March 31, 2021 $ 157,000 The fair value of the Company’s contingent consideration is determined based on the present value of projected future cash flows associated with sales based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout is derived from the Company’s estimated weighted-average cost of capital (“WACC”), which has fluctuated from 8.8% as of December 31, 2020 to 7.8% as of March 31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from 8.4% as of December 31, 2020 to 7.4% as of March 31, 2021. Improvements to the competitive landscape, higher probability of regulatory success, expanded patient population, as well as the refinement of estimated launch timelines, if approved, in certain markets outside the United States, and the aforementioned changes in discounts rates, resulted in an overal l $48.2 million increase in the estimated fair value of contingent consideration during the three months ended March 31, 2021. The current portion of total contingent consideration reflects amounts expected to be paid out within twelve months of March 31, 2021. |
INTANGIBLE ASSETS AND GOODWILL
INTANGIBLE ASSETS AND GOODWILL | 3 Months Ended |
Mar. 31, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
INTANGIBLE ASSETS AND GOODWILL | INTANGIBLE ASSETS AND GOODWILL Intangible Assets Intangible assets on the Company's condensed consolidated balance sheet are the result of the Viventia Acquisition in September 2016. The following table sets forth the composition of intangible assets as of March 31, 2021 and December 31, 2020 (in thousands): March 31, 2021 December 31, 2020 IPR&D intangible assets: Vicineum United States rights $ 31,700 $ 31,700 Vicineum European Union rights 14,700 14,700 Total Intangibles $ 46,400 $ 46,400 Goodwill Goodwill on the Company's condensed consolidated balance sheets is the result of the Viventia Acquisition in September 2016. Goodwill had a carrying value of $13.1 million as of March 31, 2021 and December 31, 2020. |
LEASES
LEASES | 3 Months Ended |
Mar. 31, 2021 | |
Leases [Abstract] | |
LEASES | LEASES The Company accounts for operating leases under ASC Topic 842, Leases. An operating lease for its 31,100 square foot facility in Winnipeg, Manitoba which consists of manufacturing, laboratory, warehouse and office space. In September 2020, the Company entered into an extension of this lease for an additional two years, through September 2022, with a right to extend the lease for one subsequent three-year term. The minimum monthly rent under this lease is $13,500 per month. In addition to rent expense, the Company expects to incur $12,300 per month in related operating expenses. Operating lease cost under this lease, including the related operating costs, was $82,000 and $76,000 for the three months ended March 31, 2021 and 2020, respectively. The asset component of the Company’s operating leases is recorded as operating lease right-of-use assets and reported within other assets on the Company's condensed consolidated balance sheets. The short-term lease liability is recorded in other current liabilities and the long term lease liability is recorded in other liabilities on the Company’s condensed consolidated balance sheets. Operating lease cost is recognized on a straight-line basis over the term of the lease. In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The short-term leases renew every three months to six months and currently extend through July and November 2021, respectively. The minimum monthly rent for these office spaces is $20,000 per month, which is subject to change if and as the Company adds or deducts space to or from the leases. The Company recorded $69,000 and $66,000 in rent expense for the three months ended March 31, 2021 and 2020, respectively. The Company's accounting policy election was disclosed in "Item 15. Exhibits and Financial Statement Schedules - Note. 3. Summary of Significant Accounting Policies" in the audited annual consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2020. |
ACCRUED EXPENSES
ACCRUED EXPENSES | 3 Months Ended |
Mar. 31, 2021 | |
Payables and Accruals [Abstract] | |
ACCRUED EXPENSES | ACCRUED EXPENSES The following table sets forth the composition of accrued expenses as of March 31, 2021 and December 31, 2020 (in thousands): March 31, December 31, 2020 Research and development $ 892 $ 1,372 Payroll-related expenses 899 1,892 Income tax payable 288 — Professional fees 1,347 684 Other 112 25 Total Accrued Expenses $ 3,538 $ 3,973 |
STOCKHOLDERS' EQUITY (DEFICIT)
STOCKHOLDERS' EQUITY (DEFICIT) | 3 Months Ended |
Mar. 31, 2021 | |
Equity [Abstract] | |
STOCKHOLDERS' EQUITY (DEFICIT) | STOCKHOLDERS' EQUITY (DEFICIT)Equity Financings ATM Offering In November 2019, the Company entered into an Open Market Sale Agreement SM (the "Sale Agreement") with Jefferies LLC ("Jefferies"), under which the Company may issue and sell shares of its common stock, par value $0.001 per share, from time to time for an aggregate sales price of up to $35 million through Jefferies (the "ATM Offering"). In October 2020 and February 2021, the Company entered into Amendment No. 1 and No. 2 (the “Amendments”) to the Sale Agreement, respectively. The Amendments revised the Sale Agreement to reflect that the Company may issue and sell shares of its common stock from time to time for an aggregate sales price of up to an additional $50 million and $34.5 million through Amendment No. 1 and No. 2 to the Sale Agreement, respectively. Sales are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Global Market or any other existing trading market for our common stock. The Company has no obligation to sell any of its common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company’s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company raised $72.6 million of net proceeds from the sale of 30.6 million shares of common stock at a weighted-average price of $2.44 per share during the three months ended March 31, 2021 compared to $3.2 million of net proceeds from the sale of 3.2 million shares of common stock at a weighted-average price of $1.02 per share during the three months ended March 31, 2020. Share issue costs, including sales agent commissions, related to the ATM Offering totaled $2.2 million and $0.1 million during the three months ended March 31, 2021and 2020, respectively. Preferred Stock Pursuant to its Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation"), the Company is authorized to issue 5.0 million shares of "blank check" preferred stock, $0.001 par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the common stock. The Company had no preferred stock issued and outstanding as of March 31, 2021 and December 31, 2020. Common Stock Pursuant to its Certificate of Incorporation, the Company is authorized to issue 200 million shares of common stock, of which 172 million and 140.4 million shares were issued and outstanding as of March 31, 2021 and December 31, 2020, respectively. In addition, the Company had reserved for issuance the following number of shares of common stock for the purposes described below as of March 31, 2021 and December 31, 2020 (in thousands): March 31, 2021 December 31, 2020 Shares of common stock issued 171,979 140,450 Shares of common stock reserved for issuance for: Warrants 1,394 2,247 Stock options 14,380 10,147 Shares available for grant under 2014 Stock Incentive Plan 760 4,863 Total shares of common stock issued and reserved for issuance 188,513 157,707 The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company’s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting. Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock. Upon the dissolution or liquidation of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock. Warrants All of the Company’s outstanding warrants are non-tradeable and permanently classified as equity because they meet the derivative scope exception under ASC Topic 815-40, Derivatives and Hedging - Contracts in Entity’s Own Equity ("ASC 815-40") . The following table sets forth the Company's warrant activity for the three months ended March 31, 2021 (in thousands): Year-to-Date Warrant Activity Issued Exercise Price (1) Expiration December 31, 2020 Issued (Exercised) (Expired) March 31, 2021 Jun-2019 $1.47 Jun-2020 — — — — — Mar-2018 $0.55* Mar-2023 1,705 — (378) — 1,327 Nov-2017 $0.55* Nov-2022 487 — (475) — 12 May-2015 $11.83 Nov-2024 28 — — — 28 Nov-2014 $11.04 Nov-2024 27 — — — 27 2,247 — (853) — 1,394 * Exercise price shown (i) reflects modification (ii) subject to further adjustment based on down round provision added by amendment described in "Item 15. Exhibits and Financial Statement Schedules - Note. 10 Stockholders' (Deficit) Equity" in the audited annual consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2020. |
(LOSS) EARNINGS PER SHARE
(LOSS) EARNINGS PER SHARE | 3 Months Ended |
Mar. 31, 2021 | |
Earnings Per Share [Abstract] | |
(LOSS) EARNINGS PER SHARE | (LOSS) EARNINGS PER SHARE A net loss cannot be diluted. Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and non-vested restricted stock awards and units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company’s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company. Additionally, an entity that presents earnings per share shall recognize the value of the effect of an anti-dilution provision in an equity-classified freestanding financial instrument in the period the anti-dilution provision is triggered. That effect shall be treated as a deemed dividend and as a reduction of income available to common stockholders in basic earnings per share. The deemed dividend is added back to income available to common stockholders when applying the treasury stock method for diluted earnings per share. For periods with net income, diluted net earnings per share is calculated by either (i) adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period as determined using the treasury stock method or (ii) the two-class method considering common stock equivalents, whichever is more dilutive. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. The two-class method was applied for the three months ended March 31, 2020. The two-class method was not applied for the three months ended March 31, 2021 as the Company’s participating securities do not have any obligation to absorb net losses. The following table illustrates the determination of (loss) earnings per share for each period presented: March 31, 2021 2020 (in thousands, except per share amounts) Basic (Loss) Earnings Per Share: Numerator: Net (loss) income $ (55,512) $ 41,564 Income attributable to participating securities - basic $ — $ 7,157 Net (loss) income attributable to common stockholders - basic $ (55,512) $ 34,407 Denominator: Weighted average common shares outstanding - basic 157,033 109,808 Net (loss) income per share applicable to common stockholders - basic $ (0.35) $ 0.31 Dilutive Earnings (Loss) Per Share: Numerator: Net (loss) income $ (55,512) $ 41,564 Income attributable to participating securities - diluted $ — $ 7,156 Net (loss) income attributable to common stockholders - diluted $ (55,512) $ 34,408 Denominator: Weighted average shares outstanding 157,033 109,808 Dilutive impact from: Stock options and employee stock purchase plan — 15 Weighted average common shares outstanding for diluted 157,033 109,823 Net (loss) income per share applicable to common stockholders - diluted $ (0.35) $ 0.31 The following potentially dilutive securities outstanding as of March 31, 2021 and 2020 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation as their effect is anti-dilutive (in thousands): Three Months Ended March 31, 2021 2020 Warrants 1,394 55 Stock options 14,380 9,703 15,774 9,758 |
SHARE-BASED COMPENSATION
SHARE-BASED COMPENSATION | 3 Months Ended |
Mar. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
SHARE-BASED COMPENSATION | SHARE-BASED COMPENSATIONThe following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its condensed consolidated statements of operations and comprehensive (loss) income for the three months ended March 31, 2021 and 2020 (in thousands): Three Months ended 2021 2020 Research and development $ 178 $ 79 General and administrative 780 328 $ 958 $ 407 2014 Stock Incentive Plan The Company's 2014 Stock Incentive Plan, as amended ("2014 Plan"), was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 Plan became effective immediately prior to the closing of the Company's IPO in February 2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards and units, stock appreciation rights and other stock-based awards, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to the Company's employees, officers, directors, consultants and advisors. Currently there are only stock options outstanding under the 2014 Plan, which generally vest over a four-year period at the rate of 25% of the grant vesting on the first anniversary of the date of grant and 6.25% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of ten years from the date of grant. There were 12 million stock options outstanding under the 2014 Plan as of March 31, 2021. At the Annual Meeting of Stockholders in June 2019, the Company's stockholders approved an amendment to the 2014 Plan that (i) increased by 7.9 million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii) eliminated the “evergreen” or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. There were 0.8 million shares of common stock available for issuance under the 2014 Plan as of March 31, 2021. 2009 Stock Incentive Plan The Company maintains a 2009 Stock Incentive Plan, as amended and restated ("2009 Plan"), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and units, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February 2014, the Company ceased granting awards under the 2009 Plan and all shares (i) available for issuance under the 2009 Plan at such time and (ii) subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are exercisable for a period of ten years from the date of grant. There were 0.1 million fully vested stock options outstanding under the 2009 Plan as of March 31, 2021. Out-of-Plan Inducement Grants From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with the Nasdaq Stock Market LLC ("Nasdaq") employment inducement grant exemption (Nasdaq Listing Rule 5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee's acceptance of employment with the Company. T here were 2.3 million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of March 31, 2021. Stock Options The following table sets forth a summary of the Company’s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the three months ended March 31, 2021: Number of Shares under Option Weighted-average Exercise Price per Option Weighted-average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2020 10,147 $1.26 8.5 $ 3,160 Granted 4,264 $3.15 Exercised (31) $1.27 Canceled or forfeited — $0.00 Outstanding at March 31, 2021 14,380 $1.82 8.6 $ 14,717 Exercisable at March 31, 2021 4,803 $1.55 7.7 $ 6,194 The Company recognized share-based compensation expense related to stock options of $1 million and $0.4 million for the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021, there was $11.4 million of total unrecognized compensation cost related to non-vested stock options which the Company expects to recognize over a weighted-average period of 3.3 years. The weighted-average grant-date fair value of stock options granted was $2.05 per option for the three months ended March 31, 2021 and $0.56 per option for the three months ended March 31, 2020. The total intrinsic value of stock options exercised during the three months ended March 31, 2021 was de minimis. For the three months ended March 31, 2021 and 2020, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model: March 31, March 31, Fair market value $3.15 $0.89 Grant exercise price $3.15 $0.89 Expected term (in years) 6.00 5.98 Risk-free interest rate 0.8 1.5 Expected volatility 75.0 71.1 Dividend yield —% —% |
EMPLOYEE BENEFIT PLANS
EMPLOYEE BENEFIT PLANS | 3 Months Ended |
Mar. 31, 2021 | |
Retirement Benefits [Abstract] | |
EMPLOYEE BENEFIT PLANS | EMPLOYEE BENEFIT PLANS 2014 Employee Stock Purchase Plan The Company's 2014 Employee Stock Purchase Plan ("2014 ESPP") was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 ESPP became effective immediately prior to the closing of the Company's IPO in February 2014 and established an initial reserve of 0.2 million shares of the Company's common stock for issuance to participating employees. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 ESPP provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the consolidated statements of changes in stockholders' equity (deficit). As of March 31, 2021, there were no shares of common stock available for sale under the 2014 ESPP. Defined Contribution Plans United States - 401(k) Plan The Company maintains a 401(k) defined contribution retirement plan which covers all of its U.S. employees. Employees are eligible to participate immediately upon their date of hire. Under the 401(k) plan, participating employees may defer up to 100% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum $4,000 per year. The expenses incurred for the periods presented were de minimis. Canada - Defined Contribution Plan |
LICENSE AGREEMENTS
LICENSE AGREEMENTS | 3 Months Ended |
Mar. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
LICENSE AGREEMENTS | LICENSE AGREEMENTS In-License Agreements License Agreement with Zurich The Company has a License Agreement with the University of Zurich ("Zurich") which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company's targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same. These patents cover some key aspects of Vicineum. The Company may be obligated to pay $0.50 million in milestone payments for the first product candidate that achieves applicable clinical development milestones. Based on current status, the Company anticipates that these milestones may be triggered by Vicineum's clinical development pathway. As part of the consideration, the Company is also obligated to pay up to a 4% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is 10% or greater, provided that the royalty rate to Zurich may not be less than 2% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded an expense of $0.3 million related to achievement of a development milestone in the three months ended December 31, 2020 due to the submission of the Company's BLA application with the FDA in December 2020. License Agreement with Micromet The Company has a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products. These patents cover some key aspects of Vicineum. Under the terms of the License Agreement with Micromet, as of March 31, 2021, the Company may be obligated to pay up to €2.4 million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $2.8 million at exchange rates in effect on March 31, 2021). Based on current development status, the Company anticipates that certain of these milestones may be triggered by the development pathway of Vicineum. The Company is also required to pay up to a 3.5% royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to 1.5% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to Micromet an annual license maintenance fee of €50,000 (approximately $58,625 at exchange rates in effect as of March 31, 2021), which can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of €0.7 million ($0.9 million) related to achievement of development milestones in the three months ended December 31, 2020, due to the submission of the Company's BLA for Vicineum with the FDA in December 2020. The Company recorded an expense of €0.5 million ($0.6 million) related to the submission of the Marketing Authorization Application (“MAA”) to the European Medicines Agency (“EMA”) for Vicineum in the three months ended March 31, 2021. License Agreement with XOMA The Company has a License Agreement with XOMA Ireland Limited ("XOMA") which grants it non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems. These patents and related know-how cover some key aspects of Vicineum. Under the terms of the License Agreement with XOMA, the Company is required to pay up to $0.25 million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. Based on current clinical status, the Company anticipates that these milestones may be triggered by Vicineum’s clinical development pathway. The Company is also required to pay a 2.5% royalty on the net sales for products incorporating XOMA’s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than 1.75% of net sales. In addition, the foregoing royalty rates are reduced by 50% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Out-License Agreements Roche License Agreement In June 2016, the Company entered into the License Agreement with Roche, pursuant to which the Company granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to the Company’s monoclonal antibody EBI-031 and all other IL-6 anti-IL-6 antagonist monoclonal antibody technology owned by the Company (collectively, the "Roche Licensed Intellectual Property"). Under the License Agreement with Roche, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (“Roche Licensed Product”) and pursue ongoing patent prosecution, at its cost. Financial Terms The Company received from Roche an upfront license fee of $7.5 million in August 2016 upon the effectiveness of the License Agreement with Roche following approval by the Company's stockholders, and Roche agreed to pay up to an additional $262.5 million upon the achievement of specified regulatory, development and commercialization milestones with respect to up to two unrelated indications. Specifically, an aggregate amount of up to $197.5 million is payable to the Company for the achievement of specified milestones with respect to the first indication, consisting of (i) $72.5 million in development milestones, the next of which is $20.0 million for initiation of the first Phase II study, (ii) $50 million in regulatory milestones and (iii) $75 million in commercialization milestones. In September 2016, Roche paid the Company the first development milestone of $22.5 million as a result of the Investigational New Drug application for EBI-031 becoming effective on or before September 15, 2016. Additional amounts of up to $65 million are payable upon the achievement of specified development and regulatory milestones in a second indication. In addition, the Company is entitled to receive royalty payments in accordance with a tiered royalty rate scale, with rates ranging from 7.5% to 15% of net sales of potential future products containing EBI-031 and up to 50% of these rates for net sales of potential future products containing other IL-6 compounds, with each of the royalties subject to reduction under certain circumstances and to the buy-out options of Roche. Buy-Out Options The License Agreement with Roche provides for two “option periods” during which Roche may elect to make a one-time payment to the Company and, in turn, terminate its diligence, milestone and royalty payment obligations under the License Agreement. Specifically, (i) Roche may exercise a buy-out option following the first dosing (“Initiation”) in the first Phase 2 study for a Licensed Product until the day before Initiation of the first Phase 3 study for a Licensed Product, in which case Roche is required to pay the Company $135 million within 30 days after Roche's exercise of such buy-out option and receipt of an invoice from the Company, or (ii) Roche may exercise a buy-out option following the day after Initiation of the first Phase 3 study for a Licensed Product until the day before the acceptance for review by the FDA or other regulatory authority of a BLA or similar application for marketing approval for a Licensed Product in either the United States or in the E.U., in which case Roche is required to pay the Company, within 30 days after Roche’s exercise of such buy-out option and receipt of an invoice from the Company, $265 million, which amount would be reduced to $220 million if none of the Company’s patent rights containing a composition of matter claim covering any compound or Roche Licensed Product has issued in the E.U. Termination Either the Company or Roche may each terminate the License Agreement with Roche if the other party breaches any of its material obligations under the agreement and does not cure such breach within a specified cure period. Roche may terminate the License Agreement with Roche following effectiveness by providing advance written notice to the Company or by providing written notice if the Company is debarred, disqualified, suspended, excluded, or otherwise declared ineligible from certain federal or state agencies or programs. The Company may terminate the License Agreement with Roche if, prior to the first filing of a BLA for a Roche Licensed Product, there is a period of twelve months where Roche is not conducting sufficient development activities with respect to the products made from the Roche Licensed Intellectual Property. OUS Business Development Partnership Agreements Qilu License Agreement On July 30, 2020, the Company and its a wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu”) pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to develop, manufacture and commercialize Vicineum (the “Licensed Product”) for the treatment of NMIBC and other types of cancer (the “Field”) in China, Hong Kong, Macau and Taiwan ("Greater China”). The Company also granted Qilu a non- exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Licensed Product in the Greater China. The Company retains (i) development, and commercialization rights in the rest of the world excluding Greater China and the Middle East and North Africa region ("MENA”) and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding China. In consideration for the rights granted by the Company, Qilu agreed to pay to the Company (i) a one-time upfront cash payment of $12 million, subject to certain tax withholdings such as income taxes and value added taxes ("VAT"), payable within 45 business days of the execution date, subject to delivery by the Company of certain know-how and other documentation related to the Licensed Product to Qilu, and (ii) milestone payments totaling up to $23 million upon the achievement of certain technology transfer, development and regulatory milestones. All payments are inclusive of VAT, which are withheld by Qilu upon payment, and for which future recovery of such taxes may be available. Qilu also agreed to pay the Company a 12% royalty based upon annual net sales of Licensed Products in Greater China. The royalties are payable on a Licensed Product-by-Licensed Product and region-by-region basis commencing on the first commercial sale of a Licensed Product in a region and continuing until the latest of (i) twelve years after the first commercial sale of such Licensed Product in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Licensed Product in such region, and (iii) the expiration of regulatory or data exclusivity for such Licensed Product in such region (collectively, the “Royalty Terms”). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Licensed Product in a particular region or no data or regulatory exclusivity of a Licensed Product in a particular region. Qilu is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the Licensed Products in the Field in Greater China. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one Licensed Product in the Field in Greater China. A joint development committee was established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans with respect to the Licensed Products in Greater China. The Company and Qilu also executed the terms and conditions of a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of the Licensed Product necessary for Qilu to develop and commercialize the Licensed Product in the Field in Greater China until the Company has completed manufacturing technology transfer to Qilu and approval of a Qilu manufactured product by the National Medical Products Administration in China ("NMPA") for the Licensed Product has been obtained. The License Agreement with Qilu will expire on a Licensed Product-by-Licensed Product and region-by-region basis on the date of the expiration of all applicable Royalty Terms. Either party may terminate the License Agreement with Qilu for the other party’s material breach following a cure period or upon certain insolvency events. Qilu has the right to receive a refund of all amounts paid to the Company in the event the License Agreement with Qilu is terminated under certain circumstances. The Qilu License Agreement with Qilu includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature. The Qilu License Agreement is subject to the provisions of Accounting Standards Codification 606, Revenue from Contracts with Customers ("ASC 606"), which was adopted effective January 1, 2018. In 2020, the initial transaction price was estimated to be $11.2 million and was based on the up-front fixed consideration of $12 million less amounts withheld for VAT. The Company concluded that its promises under the License Agreement with Qilu represented one bundled performance obligation that had been achieved as of September 30, 2020. As such, $11.2 million of the total $11.2 million transaction price was considered earned and the Company recorded $11.2 million of revenue during the three-month period ended September 30, 2020. The Investigational New Drug application for Vicineum submitted by Qilu to the Center for Drug Evaluation of the NMPA was accepted for review in January 2021 and approved in March 2021, resulting in a $3 million dollar milestone payment from Qilu, the first milestone payment out of the $23 million in potential milestone payments. The Company recorded $2.8 million (net of VAT) as license revenue during the three-month period ended March 31, 2021. The Company recorded the outstanding $2.8 million to accounts receivables as of March 31,2021. Additional consideration to be paid to the Company upon the achievement of other future milestones, as well as recoverability of VAT, will be recognized as revenue if it is expected that the amounts will be received and the amounts would not be subject to a constraint. As of March 31, 2021, none of these amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities. For the three months ended March 31, 2021, the Company recorded $0.3 million of income tax expense pursuant to the License Agreement with Qilu. The income tax expense relates to withholding taxes incurred in foreign jurisdictions and is reported as provision for income taxes on the Company's condensed consolidated statements of (operations) income and comprehensive (loss) income for the three months ended March 31, 2021. Other OUS Business Development Partnership Agreements On November 30, 2020, the Company entered into a license agreement pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the MENA region, ("the MENA License Agreement"). The Company retains development and commercialization rights in the rest of the world excluding Greater China and MENA. In consideration for the rights granted by the Company, the counterparty agreed to pay to the Company an upfront payment of $3 million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the license agreement. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 3 Months Ended |
Mar. 31, 2021 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | SUBSEQUENT EVENTS On May 3, 2021, the Company held its 2021 Annual Meeting of Stockholders. In addition to electing its Class I directors, ratifying the selection of its independent registered accounting firm and approving, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed on Schedule 14A with the SEC on March 25, 2021, stockholders approved the following proposals: • an amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000; • an amendment to the Company’s 2014 Stock Incentive Plan (the “2014 Incentive Plan”) to increase the number of shares of common stock reserved for issuance under the 2014 Incentive Plan by 12,000,000 shares of common stock; and • an amendment to the Company’s 2014 Employee Stock Purchase Plan (the “2014 ESPP”) to increase the number of shares of common stock reserved for issuance under the 2014 ESPP by 2,300,000 shares of common stock. |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 3 Months Ended |
Mar. 31, 2021 | |
Accounting Policies [Abstract] | |
Interim Financial Statements | Interim Financial Statements The accompanying unaudited interim condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X |
Use of Estimates | Use of Estimates The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company’s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets, goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); research and development expenses; revenue recognition and going concern considerations. |
Principles of Consolidation | Principles of ConsolidationThe Company’s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation. |
Foreign Currency Translation | Foreign Currency Translation The functional currency of the Company and each of its subsidiaries is the U.S. dollar. |
Recent Accounting Pronouncements | Adopted in 2021 In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments in ASU 2019-12 also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. The method with which the amendments in this ASU are to be applied varies depending on the nature of the tax item impacted by amendment. The Company adopted this guidance effective January 1, 2021, and it did not have a material impact on its financial position, results of operations or cash flows. |
FAIR VALUE MEASUREMENT AND FI_2
FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
Summary of Carrying Amounts and Fair Values of Financial Instruments Measured | The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in thousands): March 31, 2021 Fair Value Measurement Based on Carrying Amount Fair Value Quoted Prices in Active Significant Other Observable Significant Unobservable Assets: Money market funds $ 16,377 $ 16,377 $ 16,377 $ — $ — Liabilities: Contingent consideration - short term $ 9,835 $ 9,835 $ — $ — $ 9,835 Contingent consideration - long term 147,165 147,165 — — 147,165 December 31, 2020 Fair Value Measurement Based on Carrying Amount Fair Value Quoted Prices in Active Significant Other Observable Significant Unobservable Assets: Money market funds $ 16,374 $ 16,374 $ 16,374 $ — $ — Liabilities: Contingent consideration - short term $ 8,985 $ 8,985 $ — $ — $ 8,985 Contingent consideration - long term 99,855 $ 99,855 — — 99,855 |
Summary of Contingent Consideration Liability | The following table sets forth a summary of the change in the fair value of the Company's total contingent consideration liability, measured on a recurring basis at each reporting period, for the three months ended March 31, 2021 (in thousands): Balance at December 31, 2020 $108,840 Change in fair value of contingent consideration - short term 850 Change in fair value of contingent consideration - long term 47,310 Balance at March 31, 2021 $ 157,000 |
INTANGIBLE ASSETS AND GOODWILL
INTANGIBLE ASSETS AND GOODWILL (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Intangible Assets | The following table sets forth the composition of intangible assets as of March 31, 2021 and December 31, 2020 (in thousands): March 31, 2021 December 31, 2020 IPR&D intangible assets: Vicineum United States rights $ 31,700 $ 31,700 Vicineum European Union rights 14,700 14,700 Total Intangibles $ 46,400 $ 46,400 |
ACCRUED EXPENSES (Tables)
ACCRUED EXPENSES (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued Expenses | The following table sets forth the composition of accrued expenses as of March 31, 2021 and December 31, 2020 (in thousands): March 31, December 31, 2020 Research and development $ 892 $ 1,372 Payroll-related expenses 899 1,892 Income tax payable 288 — Professional fees 1,347 684 Other 112 25 Total Accrued Expenses $ 3,538 $ 3,973 |
STOCKHOLDERS' EQUITY (DEFICIT)
STOCKHOLDERS' EQUITY (DEFICIT) (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Equity [Abstract] | |
Summary of Common Stock | In addition, the Company had reserved for issuance the following number of shares of common stock for the purposes described below as of March 31, 2021 and December 31, 2020 (in thousands): March 31, 2021 December 31, 2020 Shares of common stock issued 171,979 140,450 Shares of common stock reserved for issuance for: Warrants 1,394 2,247 Stock options 14,380 10,147 Shares available for grant under 2014 Stock Incentive Plan 760 4,863 Total shares of common stock issued and reserved for issuance 188,513 157,707 |
Summary of Warrants Outstanding and Warrant Activity | The following table sets forth the Company's warrant activity for the three months ended March 31, 2021 (in thousands): Year-to-Date Warrant Activity Issued Exercise Price (1) Expiration December 31, 2020 Issued (Exercised) (Expired) March 31, 2021 Jun-2019 $1.47 Jun-2020 — — — — — Mar-2018 $0.55* Mar-2023 1,705 — (378) — 1,327 Nov-2017 $0.55* Nov-2022 487 — (475) — 12 May-2015 $11.83 Nov-2024 28 — — — 28 Nov-2014 $11.04 Nov-2024 27 — — — 27 2,247 — (853) — 1,394 * Exercise price shown (i) reflects modification (ii) subject to further adjustment based on down round provision added by amendment described in "Item 15. Exhibits and Financial Statement Schedules - Note. 10 Stockholders' (Deficit) Equity" in the audited annual consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2020. |
(LOSS) EARNINGS PER SHARE (Tabl
(LOSS) EARNINGS PER SHARE (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Earnings Per Share [Abstract] | |
Schedule of Potentially Dilutive Securities Excluded from Diluted Loss Calculation | March 31, 2021 2020 (in thousands, except per share amounts) Basic (Loss) Earnings Per Share: Numerator: Net (loss) income $ (55,512) $ 41,564 Income attributable to participating securities - basic $ — $ 7,157 Net (loss) income attributable to common stockholders - basic $ (55,512) $ 34,407 Denominator: Weighted average common shares outstanding - basic 157,033 109,808 Net (loss) income per share applicable to common stockholders - basic $ (0.35) $ 0.31 Dilutive Earnings (Loss) Per Share: Numerator: Net (loss) income $ (55,512) $ 41,564 Income attributable to participating securities - diluted $ — $ 7,156 Net (loss) income attributable to common stockholders - diluted $ (55,512) $ 34,408 Denominator: Weighted average shares outstanding 157,033 109,808 Dilutive impact from: Stock options and employee stock purchase plan — 15 Weighted average common shares outstanding for diluted 157,033 109,823 Net (loss) income per share applicable to common stockholders - diluted $ (0.35) $ 0.31 The following potentially dilutive securities outstanding as of March 31, 2021 and 2020 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation as their effect is anti-dilutive (in thousands): Three Months Ended March 31, 2021 2020 Warrants 1,394 55 Stock options 14,380 9,703 15,774 9,758 |
SHARE-BASED COMPENSATION (Table
SHARE-BASED COMPENSATION (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Schedule of Share-Based Compensation Expense | The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its condensed consolidated statements of operations and comprehensive (loss) income for the three months ended March 31, 2021 and 2020 (in thousands): Three Months ended 2021 2020 Research and development $ 178 $ 79 General and administrative 780 328 $ 958 $ 407 |
Schedule of Stock Option Activity | The following table sets forth a summary of the Company’s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the three months ended March 31, 2021: Number of Shares under Option Weighted-average Exercise Price per Option Weighted-average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2020 10,147 $1.26 8.5 $ 3,160 Granted 4,264 $3.15 Exercised (31) $1.27 Canceled or forfeited — $0.00 Outstanding at March 31, 2021 14,380 $1.82 8.6 $ 14,717 Exercisable at March 31, 2021 4,803 $1.55 7.7 $ 6,194 |
Schedule of Weighted-Average Inputs and Assumptions in Black-Scholes Option | For the three months ended March 31, 2021 and 2020, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model: March 31, March 31, Fair market value $3.15 $0.89 Grant exercise price $3.15 $0.89 Expected term (in years) 6.00 5.98 Risk-free interest rate 0.8 1.5 Expected volatility 75.0 71.1 Dividend yield —% —% |
DESCRIPTION OF BUSINESS (Detail
DESCRIPTION OF BUSINESS (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended | |
Sep. 30, 2016USD ($)shares | Mar. 31, 2021USD ($)segment | Mar. 31, 2020USD ($) | Dec. 31, 2020USD ($) | |
Variable Interest Entity [Line Items] | ||||
Number of operating segments | segment | 1 | |||
Cash and cash equivalents | $ 109,965 | $ 52,389 | ||
Net working capital | 109,200 | |||
Accumulated deficit | 371,433 | 315,921 | ||
Negative cash flows from operating activities incurred | $ (18,475) | $ (8,838) | $ (30,800) | |
Viventia Bio, Inc. | ||||
Variable Interest Entity [Line Items] | ||||
Shares of common stock issued to the selling shareholders (in shares) | shares | 4,000,000 | |||
Percentage of voting interests acquired (as a percent) | 19.90% | |||
One-time milestone payment upon first sale of product | $ 12,500 | |||
Period during which quarterly earn-outs are payable after date of net sales | 15 years | |||
Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations | 7 years | |||
Viventia Bio, Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | ||||
Variable Interest Entity [Line Items] | ||||
Percentage of net sales of quarterly earn-out payments during earn-out periods | 2.00% | |||
Viventia Bio, Inc. | Vicinium | Europe | Collaborative Arrangement, Revenue based on Specified Milestone | ||||
Variable Interest Entity [Line Items] | ||||
One-time milestone payment upon first sale of product | $ 7,000 | |||
Viventia Bio, Inc. | Vicinium | Japan | Collaborative Arrangement, Revenue based on Specified Milestone | ||||
Variable Interest Entity [Line Items] | ||||
One-time milestone payment upon first sale of product | $ 3,000 |
FAIR VALUE MEASUREMENT AND FI_3
FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Significant Unobservable Inputs (Level 3) | ||
Liabilities: | ||
Contingent consideration - long term | $ 157,000 | |
Recurring | Quoted Prices in Active Markets (Level 1) | ||
Assets: | ||
Money market funds (cash equivalents) | 16,377 | $ 16,374 |
Liabilities: | ||
Contingent consideration - short term | 0 | 0 |
Contingent consideration - long term | 0 | 0 |
Recurring | Significant Other Observable Inputs (Level 2) | ||
Assets: | ||
Money market funds (cash equivalents) | 0 | 0 |
Liabilities: | ||
Contingent consideration - short term | 0 | 0 |
Contingent consideration - long term | 0 | 0 |
Recurring | Significant Unobservable Inputs (Level 3) | ||
Assets: | ||
Money market funds (cash equivalents) | 0 | 0 |
Liabilities: | ||
Contingent consideration - short term | 9,835 | 8,985 |
Contingent consideration - long term | 147,165 | 99,855 |
Carrying Amount | ||
Liabilities: | ||
Contingent consideration - short term | 9,835 | 8,985 |
Contingent consideration - long term | 147,165 | 99,855 |
Carrying Amount | Recurring | ||
Assets: | ||
Money market funds (cash equivalents) | 16,377 | 16,374 |
Fair Value | ||
Liabilities: | ||
Contingent consideration - short term | 8,985 | |
Contingent consideration - long term | 99,855 | |
Fair Value | Recurring | ||
Assets: | ||
Money market funds (cash equivalents) | 16,377 | 16,374 |
Liabilities: | ||
Contingent consideration - short term | 9,835 | |
Contingent consideration - long term | $ 147,165 | $ 108,840 |
FAIR VALUE MEASUREMENT AND FI_4
FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Contingent Consideration (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2021USD ($) | |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] | |
Change in fair value of contingent consideration - short term | $ 850 |
Change in fair value of contingent consideration - long term | 47,310 |
Unobservable Inputs (Level 3) | |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] | |
Ending balance | $ 157,000 |
FAIR VALUE MEASUREMENT AND FI_5
FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2021USD ($) | Mar. 31, 2020USD ($) | Dec. 31, 2020 | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||
Royalty rate | 2.00% | ||
Change in fair value of contingent consideration | $ 48,160 | $ (53,700) | |
Discount Rate | |||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||
Weighted-average cost of capital | 780.00% | ||
Discount Rate | Minimum | |||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||
Contingent consideration liability measurements used | 0.084 | ||
Discount Rate | Maximum | |||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||
Contingent consideration liability measurements used | 0.088 |
INTANGIBLE ASSETS AND GOODWIL_2
INTANGIBLE ASSETS AND GOODWILL (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Finite-Lived Intangible Assets [Line Items] | ||
Goodwill | $ 13,064 | $ 13,064 |
Vicinium | IPR&D intangible assets | ||
Finite-Lived Intangible Assets [Line Items] | ||
Total Intangibles | 46,400 | 46,400 |
Vicinium | IPR&D intangible assets | United States | ||
Finite-Lived Intangible Assets [Line Items] | ||
Total Intangibles | 31,700 | 31,700 |
Vicinium | IPR&D intangible assets | Europe | ||
Finite-Lived Intangible Assets [Line Items] | ||
Total Intangibles | $ 14,700 | $ 14,700 |
LEASES - Narrative (Details)
LEASES - Narrative (Details) | 3 Months Ended | |
Mar. 31, 2021USD ($)ft²term | Mar. 31, 2020USD ($) | |
Lessee, Lease, Description [Line Items] | ||
Monthly rent | $ 20,000 | |
Rent expense | $ 69,000 | $ 66,000 |
Canada | ||
Lessee, Lease, Description [Line Items] | ||
Office space (in square feet) | ft² | 31,100 | |
Lease term | 2 years | |
Renewal option | term | 1 | |
Renewal term | 3 years | |
Monthly rent | $ 13,500 | |
Related operating expenses, per month | 12,300 | |
Operating lease cost, including related operating cost | $ 82,000 | $ 76,000 |
ACCRUED EXPENSES - Composition
ACCRUED EXPENSES - Composition of Accrued Expenses (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Payables and Accruals [Abstract] | ||
Research and development | $ 892 | $ 1,372 |
Payroll-related expenses | 899 | 1,892 |
Income tax payable | 288 | 0 |
Professional fees | 1,347 | 684 |
Other | 112 | 25 |
Total Accrued Expenses | $ 3,538 | $ 3,973 |
STOCKHOLDERS' EQUITY (DEFICIT_2
STOCKHOLDERS' EQUITY (DEFICIT) - Equity Financing (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 1 Months Ended | 3 Months Ended | 13 Months Ended | ||||
Feb. 28, 2021 | Nov. 30, 2019 | Mar. 31, 2021 | Sep. 30, 2020 | Mar. 31, 2020 | Oct. 31, 2021 | Dec. 31, 2020 | |
Class of Stock [Line Items] | |||||||
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 | |||||
Issuance of common stock, issuance costs | $ 2.2 | $ 0.1 | $ 0.1 | ||||
ATM Facility | |||||||
Class of Stock [Line Items] | |||||||
Aggregate sales price | $ 35 | ||||||
Common stock, par value (in dollars per share) | $ 0.001 | ||||||
Sale Of Stock, Additional Shares Authorized For Sale | $ 34.5 | $ 50 | |||||
Commission fixed rate | 3.00% | ||||||
Proceeds from sale of stock | $ 72.6 | $ 3.2 | |||||
Sale of stock, shares issued (in shares) | 30.6 | 3.2 | |||||
Stock price per share (in dollars per share) | $ 2.44 | $ 1.02 |
STOCKHOLDERS' EQUITY (DEFICIT_3
STOCKHOLDERS' EQUITY (DEFICIT) - Preferred Stock (Details) - $ / shares | Mar. 31, 2021 | Dec. 31, 2020 |
Equity [Abstract] | ||
Preferred stock, shares authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
STOCKHOLDERS' EQUITY (DEFICIT_4
STOCKHOLDERS' EQUITY (DEFICIT) - Common Stock (Details) - shares | Mar. 31, 2021 | Dec. 31, 2020 |
Equity [Abstract] | ||
Common stock, shares authorized (in shares) | 200,000,000 | 200,000,000 |
Common stock, shares issued (in shares) | 171,978,799 | 140,449,647 |
Common stock, shares outstanding (in shares) | 171,978,799 | 140,449,647 |
STOCKHOLDERS' EQUITY (DEFICIT_5
STOCKHOLDERS' EQUITY (DEFICIT) - Summary of Common Stock Issued and Reserved for Issuance (Details) - shares | Mar. 31, 2021 | Dec. 31, 2020 |
Class of Warrant or Right [Line Items] | ||
Common stock, shares issued (in shares) | 171,978,799 | 140,449,647 |
Shares of common stock reserved for issuance for: | ||
Total shares of common stock issued and reserved for issuance (in shares) | 188,513,000 | 157,707,000 |
Warrants | ||
Shares of common stock reserved for issuance for: | ||
Shares of common stock available for issuance (in shares) | 1,394,000 | 2,247,000 |
Stock options | ||
Shares of common stock reserved for issuance for: | ||
Shares of common stock available for issuance (in shares) | 14,380,000 | 10,147,000 |
Shares available for grant under 2014 Stock Incentive Plan | ||
Shares of common stock reserved for issuance for: | ||
Shares of common stock available for issuance (in shares) | 760,000 | 4,863,000 |
STOCKHOLDERS' EQUITY (DEFICIT_6
STOCKHOLDERS' EQUITY (DEFICIT) - Warrants (Details) - $ / shares shares in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Warrant Or Right Outstanding [Roll Forward] | ||
Warrants outstanding, beginning balance (in shares) | 2,247 | |
Warrants Issued (in shares) | 0 | |
Warrants Exercised (in shares) | (853) | |
Warrants Expired (in shares) | 0 | |
Warrants outstanding, ending balance (in shares) | 1,394 | |
Warrants, Expiring June 2020 | ||
Warrant Or Right Outstanding [Roll Forward] | ||
Exercise price (in dollars per share) | $ 1.47 | |
Warrants outstanding, beginning balance (in shares) | 0 | |
Warrants Issued (in shares) | 0 | |
Warrants Exercised (in shares) | 0 | |
Warrants Expired (in shares) | 0 | |
Warrants outstanding, ending balance (in shares) | 0 | |
Warrants, Expiring March 2023 | ||
Warrant Or Right Outstanding [Roll Forward] | ||
Exercise price (in dollars per share) | $ 0.55 | |
Warrants outstanding, beginning balance (in shares) | 1,705 | |
Warrants Issued (in shares) | 0 | |
Warrants Exercised (in shares) | (378) | |
Warrants Expired (in shares) | 0 | |
Warrants outstanding, ending balance (in shares) | 1,327 | |
Warrants, Expiring November 2022 | ||
Warrant Or Right Outstanding [Roll Forward] | ||
Exercise price (in dollars per share) | $ 0.55 | |
Warrants outstanding, beginning balance (in shares) | 487 | |
Warrants Issued (in shares) | 0 | |
Warrants Exercised (in shares) | (475) | |
Warrants Expired (in shares) | 0 | |
Warrants outstanding, ending balance (in shares) | 12 | |
Warrants, Expiring November 2024 | ||
Warrant Or Right Outstanding [Roll Forward] | ||
Exercise price (in dollars per share) | $ 11.83 | |
Warrants outstanding, beginning balance (in shares) | 28 | |
Warrants Issued (in shares) | 0 | |
Warrants Exercised (in shares) | 0 | |
Warrants Expired (in shares) | 0 | |
Warrants outstanding, ending balance (in shares) | 28 | |
Warrants, Expiring November 2024 | ||
Warrant Or Right Outstanding [Roll Forward] | ||
Exercise price (in dollars per share) | $ 11.04 | |
Warrants outstanding, beginning balance (in shares) | 27 | |
Warrants Issued (in shares) | 0 | |
Warrants Exercised (in shares) | 0 | |
Warrants Expired (in shares) | 0 | |
Warrants outstanding, ending balance (in shares) | 27 |
(LOSS) EARNINGS PER SHARE (Deta
(LOSS) EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Numerator: | ||
Net loss | $ (55,512) | $ 41,564 |
Income attributable to participating securities - basic | 0 | 7,157 |
Net (loss) income attributable to common stockholders - basic | $ (55,512) | $ 34,407 |
Denominator: | ||
Weighted-average common shares outstanding - basic (in shares) | 157,033,000 | 109,808,000 |
Net (loss) per common share - basic (in dollars per share) | $ (0.35) | $ 0.31 |
Dilutive Earnings (Loss) Per Share: | ||
Income attributable to participating securities - diluted | $ 0 | $ 7,156 |
Net (loss) income attributable to common stockholders - diluted | $ (55,512) | $ 34,408 |
Dilutive impact from: | ||
Stock options and employee stock purchase plan (in shares) | 0 | 15,000 |
Weighted-average common shares outstanding for diluted (in shares) | 157,033,000 | 109,823,000 |
Net income (loss) per share applicable to common stockholders - diluted (in dollars per share) | $ (0.35) | $ 0.31 |
Potentially dilutive securities outstanding | ||
Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares) | 15,774,000 | 9,758,000 |
Warrants | ||
Potentially dilutive securities outstanding | ||
Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares) | 1,394,000 | 55,000 |
Stock options | ||
Potentially dilutive securities outstanding | ||
Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares) | 14,380,000 | 9,703,000 |
SHARE-BASED COMPENSATION - Shar
SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based compensation expense | $ 958 | $ 407 |
Research and development | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based compensation expense | 178 | 79 |
General and administrative | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based compensation expense | $ 780 | $ 328 |
SHARE-BASED COMPENSATION - Narr
SHARE-BASED COMPENSATION - Narrative (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | ||
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Stock options outstanding (in shares) | 14,380 | 10,147 | |
Share-based compensation expense | $ 958 | $ 407 | |
Unrecognized compensation cost, non-vested stock options | $ 11,400 | ||
Weighted-average period to recognize non-vested stock options | 3 years 3 months 18 days | ||
Weighted-average grant-date fair value of stock options granted (in dollars per share) | $ 2.05 | $ 0.56 | |
Employee | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Stock options outstanding (in shares) | 2,300 | ||
Stock options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Shares of common stock available for issuance (in shares) | 14,380 | 10,147 | |
2014 Stock Incentive Plan | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Stock options outstanding (in shares) | 12,000 | ||
2014 Stock Incentive Plan | Stock options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Award vesting period | 4 years | ||
Period exercisable from date of grant | 10 years | ||
Shares of common stock available for issuance (in shares) | 800 | ||
2009 Stock Incentive Plan | Stock options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Period exercisable from date of grant | 10 years | ||
Vested stock options outstanding (in shares) | 100 | ||
Vesting on the First Anniversary of Date of Grant | 2014 Stock Incentive Plan | Stock options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share-based compensation, vesting rate | 25.00% | ||
Vesting at End of Each Successive Three-Month Period Thereafter | 2014 Stock Incentive Plan | Stock options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share-based compensation, vesting rate | 6.25% |
SHARE-BASED COMPENSATION - Stoc
SHARE-BASED COMPENSATION - Stock Options (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2021 | Dec. 31, 2020 | |
Number of Shares under Option (in thousands) | ||
Outstanding at beginning of period (in shares) | 10,147 | |
Granted (in shares) | 4,264 | |
Exercised (in shares) | (31) | |
Canceled or forfeited (in shares) | 0 | |
Outstanding at end of period (in shares) | 14,380 | 10,147 |
Exercisable at end of period (in shares) | 4,803 | |
Weighted-average Exercise Price per Option | ||
Outstanding at beginning of period (in dollars per share) | $ 1.26 | |
Granted (in dollars per share) | 3.15 | |
Exercised (in dollars per share) | 1.27 | |
Canceled or forfeited (in dollars per share) | 0 | |
Outstanding at end of period (in dollars per share) | 1.82 | $ 1.26 |
Exercisable (in dollars per share) | $ 1.55 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] | ||
Weighted-average Remaining Contractual Life (in years), Outstanding | 8 years 7 months 6 days | 8 years 6 months |
Weighted-average Remaining Contractual Life (in years), Exercisable | 7 years 8 months 12 days | |
Aggregate Intrinsic Value, Outstanding | $ 14,717 | $ 3,160 |
Aggregate Intrinsic Value, Exercisable | $ 6,194 |
SHARE-BASED COMPENSATION - Weig
SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details) - $ / shares | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Share-based Payment Arrangement [Abstract] | ||
Fair market value (in dollars per share) | $ 3.15 | $ 0.89 |
Grant exercise price (in dollars per share) | $ 3.15 | $ 0.89 |
Expected term (in years) | 6 years | 5 years 11 months 23 days |
Risk-free interest rate | 0.80% | 1.50% |
Expected volatility | 75.00% | 71.10% |
Dividend yield | 0.00% | 0.00% |
EMPLOYEE BENEFIT PLANS (Details
EMPLOYEE BENEFIT PLANS (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Feb. 28, 2014 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Defined contribution retirement plan, maximum employee contribution deferred | 100.00% | |
Discretionary match per participating employee, maximum | $ 4,000 | |
Employer matching contribution, percent of employees' eligible compensation | 4.00% | |
2014 Employee Stock Purchase Plan | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Shares of common stock available for issuance (in shares) | 200,000 | |
Common stock purchase price, discount rate | 15.00% | |
Common stock available for sale (in shares) | 0 |
LICENSE AGREEMENTS (Details)
LICENSE AGREEMENTS (Details) € in Thousands | Jul. 30, 2020USD ($) | Sep. 30, 2016USD ($) | Aug. 31, 2016USD ($) | Jun. 30, 2016USD ($)option | Mar. 31, 2021USD ($) | Mar. 31, 2021EUR (€) | Sep. 30, 2020USD ($) | Mar. 31, 2020USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2020EUR (€) |
Organization And Basis Of Presentation [Line Items] | ||||||||||
Royalty rate | 2.00% | |||||||||
License revenue | $ 4,310,000 | $ 0 | ||||||||
Provision for income taxes | 288,000 | $ 0 | ||||||||
Transaction price | $ 11,200,000 | $ 11,200,000 | ||||||||
Qilu Pharmaceutical Co., Ltd. | Licensing Agreements | ||||||||||
Organization And Basis Of Presentation [Line Items] | ||||||||||
Potential milestone payments | 23,000,000 | |||||||||
Cash payment | $ 12,000,000 | 12,000,000 | ||||||||
Total milestone payments | $ 23,000,000 | |||||||||
Royalty payment based on annual net sales | 12.00% | |||||||||
License revenue | 2,800,000 | $ 11,200,000 | ||||||||
Milestone payment | 3,000,000 | |||||||||
Outstanding payments | $ 2,800,000 | |||||||||
University of Zurich | ||||||||||
Organization And Basis Of Presentation [Line Items] | ||||||||||
License agreement, royalty on net product sales, percentage | 4.00% | 4.00% | ||||||||
License agreement, rate requiring reduction in the amount of royalties owed | 10.00% | 10.00% | ||||||||
License agreement, royalty on net product sales, minimum | 2.00% | 2.00% | ||||||||
Expenses related to achievement of development milestone | 300,000 | |||||||||
University of Zurich | Collaborative Arrangement, Revenue Based on Clinical Development Milestone | ||||||||||
Organization And Basis Of Presentation [Line Items] | ||||||||||
License agreement, amount payable upon achievement of specified milestone | $ 500,000 | |||||||||
Micromet AG | ||||||||||
Organization And Basis Of Presentation [Line Items] | ||||||||||
License agreement, royalty on net product sales, percentage | 3.50% | 3.50% | ||||||||
Expenses related to achievement of development milestone | $ 600,000 | € 500 | 900,000 | € 700 | ||||||
Potential milestone payments | $ 2,800,000 | € 2,400 | ||||||||
License Agreement, royalty payment, reduction, conditions not met | 1.50% | 1.50% | ||||||||
License maintenance fees | $ 58,625 | € 50 | ||||||||
XOMA Ireland Limited | ||||||||||
Organization And Basis Of Presentation [Line Items] | ||||||||||
License agreement, amount payable upon achievement of specified milestone | $ 250,000 | |||||||||
License agreement, royalty on net product sales, percentage | 2.50% | 2.50% | ||||||||
License agreement, rate requiring reduction in the amount of royalties owed | 50.00% | 50.00% | ||||||||
License agreement, royalty on net product sales, minimum | 1.75% | 1.75% | ||||||||
Roche | ||||||||||
Organization And Basis Of Presentation [Line Items] | ||||||||||
Up-front license fee | $ 7,500,000 | |||||||||
Additional up-front fee | 262,500,000 | |||||||||
License agreement, option periods | option | 2 | |||||||||
License agreement, buyout amount under first option period | $ 135,000,000 | |||||||||
License agreement, period to pay buyout option once exercised | 30 days | |||||||||
License agreement, buyout amount under second option period | $ 265,000,000 | |||||||||
License agreement, buyout amount under second option period, upon non-issuance of patent rights or licensed product | $ 220,000,000 | |||||||||
Roche | First Indication | ||||||||||
Organization And Basis Of Presentation [Line Items] | ||||||||||
License agreement, amount payable upon achievement of specified milestone | 197,500,000 | |||||||||
Roche | Collaborative Arrangement, Revenue Based on Development Milestone | ||||||||||
Organization And Basis Of Presentation [Line Items] | ||||||||||
License agreement, amount payable upon achievement of specified milestone | 72,500,000 | |||||||||
Roche | Collaborative Arrangement, Revenue Based on Regulatory Milestone | ||||||||||
Organization And Basis Of Presentation [Line Items] | ||||||||||
License agreement, amount payable upon achievement of specified milestone | 50,000,000 | |||||||||
Roche | Collaborative Arrangement, Revenue Based on Commercialization Milestone | ||||||||||
Organization And Basis Of Presentation [Line Items] | ||||||||||
License agreement, amount payable upon achievement of specified milestone | 75,000,000 | |||||||||
Roche | Collaborative Arrangement, Revenue Based on Development Milestone, Phase II | ||||||||||
Organization And Basis Of Presentation [Line Items] | ||||||||||
License agreement, amount payable upon achievement of specified milestone | $ 20,000,000 | |||||||||
Roche | Second Indication | ||||||||||
Organization And Basis Of Presentation [Line Items] | ||||||||||
License agreement, amount payable upon achievement of specified milestone | $ 65,000,000 | |||||||||
Roche | EBI-031 | Minimum | ||||||||||
Organization And Basis Of Presentation [Line Items] | ||||||||||
Royalty rate | 7.50% | |||||||||
Roche | EBI-031 | Maximum | ||||||||||
Organization And Basis Of Presentation [Line Items] | ||||||||||
Royalty rate | 15.00% | |||||||||
Roche | EBI-031 | Collaborative Arrangement, Revenue Based on Development Milestone | ||||||||||
Organization And Basis Of Presentation [Line Items] | ||||||||||
License agreement, amount payable upon achievement of specified milestone | $ 22,500,000 | |||||||||
Roche | IL-6 | ||||||||||
Organization And Basis Of Presentation [Line Items] | ||||||||||
Royalty rate | 50.00% | |||||||||
MENA License Agreement | Licensing Agreements | ||||||||||
Organization And Basis Of Presentation [Line Items] | ||||||||||
Cash payment | 3,000,000 | |||||||||
Provision for income taxes | $ 300,000 | |||||||||
Transaction price | $ 1,500,000 |
SUBSEQUENT EVENT - Narrative (D
SUBSEQUENT EVENT - Narrative (Details) - shares | May 03, 2021 | May 02, 2021 | Mar. 31, 2021 | Dec. 31, 2020 |
Subsequent Event [Line Items] | ||||
Common stock, shares authorized (in shares) | 200,000,000 | 200,000,000 | ||
Subsequent Event | ||||
Subsequent Event [Line Items] | ||||
Common stock, shares authorized (in shares) | 400,000,000 | 200,000,000 | ||
Subsequent Event | 2014 Stock Incentive Plan | ||||
Subsequent Event [Line Items] | ||||
Number of shares reserved for issuance (in shares) | 12,000,000 | |||
Subsequent Event | 2014 ESPP | ||||
Subsequent Event [Line Items] | ||||
Number of shares reserved for issuance (in shares) | 2,300,000 |